About
Altoida is an advanced digital health platform designed to revolutionize neurological diagnostics by enabling earlier, more accurate detection of cognitive decline. Built on two decades of scientific research, the Altoida NeuroMarker Platform combines machine learning, augmented reality, and multi-modal sensor data — including motion, speech, and touch — to deliver deep, evidence-based cognitive assessments in as little as 10 minutes. Unlike traditional pen-and-paper neuropsychological tests that require trained specialists, take up to 4 hours, and lack sensitivity for early-stage impairment, Altoida's self-administered in-clinic assessment provides real-time, objective results after a single visit. The platform is designed for primary care settings, empowering healthcare providers who are not neurology specialists to identify mild cognitive impairment and Alzheimer's disease at the earliest possible stage — when treatment interventions are most effective. Key capabilities include real-time cognition monitoring, longitudinal progress tracking to evaluate disease progression, and personalized treatment pathway guidance based on specific cognitive deficits. The platform is currently focused on MCI and Alzheimer's disease but is expanding to cover a broader range of central nervous system disorders. Altoida is intended for healthcare institutions, neurologists, primary care physicians, and clinical researchers seeking to enhance patient outcomes through earlier diagnosis and more targeted care strategies. The platform is currently in investigational use and has not yet received FDA clearance for commercial sale.
Key Features
- 10-Minute Self-Administered Assessment: Patients complete a digital cognitive test in just 10 minutes using a smart tablet, eliminating the need for a trained specialist to administer the test and dramatically reducing time to results.
- NeuroMarker Sensor Fusion: Captures rich multi-modal data — motion, speech, and touch — during neuroscience-driven AR tasks that simulate daily activities, enabling highly sensitive early detection of cognitive impairment.
- Real-Time Objective Results: Delivers instant, data-driven cognitive insights to clinicians during the same visit, enabling faster and more informed treatment decisions compared to traditional assessments that take months to interpret.
- Longitudinal Cognitive Monitoring: Tracks changes in cognitive function over time, allowing clinicians to evaluate disease progression, adjust medications, and monitor the impact of care strategies on patient outcomes.
- Personalized Treatment Guidance: Identifies specific areas of cognitive decline to help healthcare providers design individualized treatment plans tailored to each patient's unique cognitive profile.
Use Cases
- Screening patients for early-stage mild cognitive impairment (MCI) during routine primary care visits without requiring a specialist.
- Monitoring longitudinal cognitive progression in patients diagnosed with Alzheimer's disease to guide medication and care adjustments.
- Supporting clinical research studies on cognitive decline by providing standardized, sensor-based, reproducible assessment data.
- Streamlining neurology clinic workflows by replacing multi-hour neuropsychological evaluations with rapid 10-minute digital assessments.
- Enabling earlier treatment interventions for MCI patients by identifying cognitive decline at the most actionable stage of disease progression.
Pros
- Dramatically Faster Than Traditional Testing: Reduces neuropsychological assessment time from 2–4 hours to just 10 minutes, cutting wait times for treatment decisions and improving clinical throughput.
- Higher Sensitivity for Early-Stage MCI: Neuroscience-driven tasks and sensor-based data capture subtle cognitive markers that traditional pen-and-paper tests frequently miss, enabling earlier intervention.
- Designed for Primary Care Settings: No neurology specialist is required to administer the test, making advanced cognitive screening accessible in general practice clinics and broadening patient reach.
- Built on Rigorous Scientific Research: Backed by over two decades of neuroscience research, ensuring the platform's assessments are transparent, measurable, and evidence-based.
Cons
- Not Yet FDA Cleared: The platform is currently approved for investigational use only and has not received FDA clearance or approval, limiting its availability for broad commercial clinical deployment.
- Requires In-Clinic Tablet Hardware: The assessment must be completed in a clinical setting using a compatible smart tablet, which may require infrastructure investment and limits remote or at-home use.
- Narrow Disease Scope Currently: The platform is primarily focused on MCI and Alzheimer's disease at this stage, with expansion to other central nervous system conditions still in progress.
Frequently Asked Questions
What is the Altoida NeuroMarker Platform?
The Altoida NeuroMarker Platform is a digital cognitive assessment system that uses AI, augmented reality, and sensor data to detect early signs of mild cognitive impairment and Alzheimer's disease. It delivers objective, real-time results in just 10 minutes via a self-administered in-clinic test on a smart tablet.
How long does the Altoida cognitive assessment take?
The Altoida Digital Cognitive Assessment takes approximately 10 minutes to complete and is self-administered by the patient during a single clinic visit, compared to 2–4 hours for traditional neuropsychological evaluations.
Has Altoida received FDA approval?
No. As of the current date, Altoida's platform is intended for investigational use only. It has not received FDA clearance or approval and is not available for commercial sale.
Who is Altoida designed for?
Altoida is designed for healthcare providers including neurologists, primary care physicians, and clinical researchers who need a fast, sensitive, and objective tool for detecting and monitoring cognitive decline in patients.
How does Altoida compare to standard cognitive assessments?
Traditional pen-and-paper assessments require a trained neuropsychologist, take 2–4 hours, and often lack the sensitivity to detect early-stage MCI. Altoida's platform is self-administered, takes 10 minutes, uses sensor and AR data for greater sensitivity, and delivers real-time results — significantly improving speed, accuracy, and accessibility of cognitive diagnostics.
